ResMed Inc. (NYSE:RMD) insider James Hollingshead sold 7,140 shares of ResMed stock in a transaction dated Friday, July 14th. The stock was sold at an average price of $77.43, for a total value of $552,850.20. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Shares of ResMed Inc. (NYSE:RMD) traded up 0.04% on Monday, reaching $77.62. The company’s stock had a trading volume of 417,805 shares. ResMed Inc. has a 1-year low of $56.59 and a 1-year high of $79.44. The company has a market capitalization of $11.01 billion, a price-to-earnings ratio of 34.04 and a beta of 0.84. The stock has a 50-day moving average price of $72.98 and a 200-day moving average price of $69.45.

ResMed (NYSE:RMD) last posted its quarterly earnings data on Thursday, April 27th. The medical equipment provider reported $0.71 earnings per share for the quarter, topping analysts’ consensus estimates of $0.70 by $0.01. ResMed had a return on equity of 22.53% and a net margin of 15.96%. The company had revenue of $514.20 million during the quarter, compared to analysts’ expectations of $525.84 million. During the same period last year, the firm earned $0.68 EPS. The firm’s revenue for the quarter was up 13.3% on a year-over-year basis. On average, equities research analysts forecast that ResMed Inc. will post $2.80 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This piece of content was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of US & international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/07/17/james-hollingshead-sells-7140-shares-of-resmed-inc-rmd-stock.html.

A number of hedge funds have recently bought and sold shares of RMD. Cape Cod Five Cents Savings Bank boosted its stake in ResMed by 1.0% in the second quarter. Cape Cod Five Cents Savings Bank now owns 48,643 shares of the medical equipment provider’s stock worth $3,787,000 after buying an additional 477 shares during the last quarter. Oregon Public Employees Retirement Fund boosted its stake in ResMed by 5.3% in the second quarter. Oregon Public Employees Retirement Fund now owns 69,077 shares of the medical equipment provider’s stock worth $5,379,000 after buying an additional 3,449 shares during the last quarter. Mn Services Vermogensbeheer B.V. boosted its stake in ResMed by 511.3% in the second quarter. Mn Services Vermogensbeheer B.V. now owns 22,979 shares of the medical equipment provider’s stock worth $1,789,000 after buying an additional 19,220 shares during the last quarter. National Pension Service boosted its stake in ResMed by 10.0% in the second quarter. National Pension Service now owns 154,347 shares of the medical equipment provider’s stock worth $11,899,000 after buying an additional 14,018 shares during the last quarter. Finally, State of Alaska Department of Revenue boosted its stake in ResMed by 6.6% in the second quarter. State of Alaska Department of Revenue now owns 9,529 shares of the medical equipment provider’s stock worth $742,000 after buying an additional 590 shares during the last quarter. 60.69% of the stock is owned by institutional investors.

RMD has been the subject of a number of research reports. J P Morgan Chase & Co downgraded ResMed from an “overweight” rating to a “neutral” rating and decreased their target price for the stock from $72.00 to $71.00 in a report on Thursday, April 20th. Zacks Investment Research raised ResMed from a “sell” rating to a “hold” rating in a report on Wednesday, April 12th. William Blair reaffirmed an “outperform” rating on shares of ResMed in a report on Thursday, April 13th. BMO Capital Markets reaffirmed a “hold” rating on shares of ResMed in a report on Friday, May 12th. Finally, Citigroup Inc. downgraded ResMed from a “buy” rating to a “neutral” rating in a report on Friday, April 28th. Four analysts have rated the stock with a sell rating, four have given a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $64.50.

ResMed Company Profile

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Insider Buying and Selling by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.